Signal release
The brochure illustrates acetylcholine release from the presynaptic nerve ending.
AMULYN synthetic snake-venom-like tripeptide for eye creams, eye masks and anti-wrinkle skincare formulations. Explore peptide mechanism, test data and sourcing.
AMULYN Cosmetic Peptide Ingredient
A synthetic cosmetic peptide ingredient positioned for eye masks, eye creams and anti-wrinkle skincare development. The supplied product brochure describes a high-purity peptide powder and a liquid solution format inspired by the action mechanism of Waglerin-1.
Ingredient profile
The supplied brochure describes this ingredient as a synthetic tripeptide that models the action mechanism of Waglerin-1 from Temple Viper venom. It is synthesized from amino acids and is not obtained by extracting snake venom.
The product profile positions it for immediate wrinkle-care concepts, especially functional eye masks, eye creams and anti-wrinkle skincare products. Final product claims must be reviewed against the finished formulation, substantiation package and destination-market requirements.
Visual library
Replace the image placeholders with approved product, laboratory, structure, packaging and application images. Use owned or licensed visuals only.
Recommended image set: peptide powder, chemical structure, mechanism diagram, transparent solution, laboratory testing, eye cream, eye mask, finished packaging, quality-control area and shipping carton.
Mechanism concept
According to the supplied brochure, the peptide is designed to interact with the ε subunit of the postsynaptic nicotinic acetylcholine receptor. The brochure describes the intended sequence as reducing acetylcholine binding, limiting receptor opening and reducing the muscle-contraction signal.
The same source describes the concept as fast-acting, long-lasting and reversible. These statements are product-brochure claims and should be supported with the applicable technical and cosmetic substantiation documents before being used in advertising or on-pack copy.
Action pathway
This section translates the source brochure's diagram into a buyer-friendly sequence. It is not a medical or clinical treatment description.
The brochure illustrates acetylcholine release from the presynaptic nerve ending.
The peptide is described as interacting with the postsynaptic nicotinic acetylcholine receptor.
The brochure describes reduced neurotransmitter-driven muscle movement in the target mechanism.
The cosmetic positioning is smoother-looking skin and wrinkle-care support in finished products.
Product applications
The supplied brochure lists the following application directions. Confirm suitability in the buyer's own formulation system and destination-market compliance review.
Use the peptide as an ingredient direction for eye-care formulas developed around wrinkle appearance and skin-smoothing claims.
The brochure specifically lists functional eye masks as an application direction for the peptide.
Suitable for formulation discussions involving anti-wrinkle skincare concepts, subject to finished-product testing and claim review.
Technical profile
Use this summary for initial sourcing discussions. Request the current technical data sheet, specification, COA and regulatory documents before approval.
| Item | Information | Publication note |
|---|---|---|
| Product name | Snake-Venom-Like Tripeptide / 类蛇毒三肽 | English naming follows the supplied brochure concept. |
| INCI shown | Dipeptide Diaminobutyroyl Benzylamide; another brochure section shows Dipeptide Diaminobutyroyl Benzylamide Diacetate | Confirm the commercial form and current INCI documentation before final publication. |
| CAS | 823202-99-9 | Shown in the product profile; verify against the purchased material's documentation. |
| Sequence | H-β-Ala-Pro-Dab-NH-Bzl | As shown in the product profile. |
| Molecular formula | C₁₉H₂₉N₅O₃ | As shown in the product profile. |
| Molecular weight | 375.5 g/mol | As shown in the product profile. |
| Powder description | High-purity peptide powder | No exact powder purity percentage is stated in the supplied brochure. |
| Liquid solution | 2,500 ppm | Format-specific information; do not use as the powder concentration. |
| Liquid solution addition level | 1.0-8.0% | Listed for the liquid solution; confirm the correct use level for the purchased format. |
| Storage | Protect from light; keep dry and sealed; refrigerate at 2-8°C | The brochure states room-temperature transport is possible. |
| Packaging | __PACKAGING_TO_CONFIRM__ | The brochure's 1 kg / 5 kg / 10 kg / 25 kg options are general liquid-peptide packaging information, not confirmed for this product. |
Important: the supplied brochure uses different INCI forms in different sections. Do not publish a final ingredient declaration until the supplier confirms the exact commercial form.
In-vitro test reference
The brochure reports an in-vitro elastase inhibition test. These results are not clinical results and should not be presented as proof of treatment or guaranteed finished-product performance.
Reported elastase inhibition rate in the supplied brochure.
Reported elastase inhibition rate in the supplied brochure.
Reported elastase inhibition rate in the supplied brochure.
Test reference from the brochure: blank control, positive control EGCG, sample and control wells; 50 µL elastase was added except to the blank group, followed by incubation at 37°C for 10 minutes before OD measurement. The positive-control rate shown was 88.47%. Request the original test report and method validation before using these values in a commercial claim.
Formulation support
The brochure references both a high-purity powder and a 2,500 ppm liquid solution. The liquid solution is listed at 1.0-8.0% addition. Powder use level, solvent system, compatibility, processing temperature and preservation requirements should be confirmed from the relevant technical documentation.
Responsible product communication
FAQ
It is a synthetic cosmetic peptide ingredient described in the supplied brochure as modelling the action mechanism of Waglerin-1 from Temple Viper venom. It is synthesized from amino acids and is not extracted from snake venom.
The brochure uses both Dipeptide Diaminobutyroyl Benzylamide and Dipeptide Diaminobutyroyl Benzylamide Diacetate in different sections. Confirm the commercial form and current INCI documentation before using one form on a label or regulatory file.
The brochure lists functional eye masks, eye creams and anti-wrinkle skincare products. Final suitability and claims should be validated in the finished formulation and destination market.
The brochure lists 1.0-8.0% for the 2,500 ppm liquid solution. It does not provide a powder addition level.
Protect it from light, keep it dry and sealed, and refrigerate at 2-8°C. The brochure states that room-temperature transport is possible.
Start a peptide sourcing discussion
For a relevant quotation and technical review, include powder or liquid format, target product, expected use level, trial quantity, packaging requirement, destination market and documentation needs.
1208, Building B, Huixin 1BC, No. 1 Zhang Bayi Road, High-tech Zone, Xi'an, Shaanxi, China
0086-199 9282 1268
Copyright @ 2024 AMULYN Corp All rights reserved.
Technical Support | Site Map